{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progressive+Multiple+Sclerosis&page=2",
    "query": {
      "condition": "Progressive Multiple Sclerosis",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progressive+Multiple+Sclerosis&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-07T19:51:25.486Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07224373",
      "title": "An Open-label Study of AZD0120 in Adults With Multiple Sclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "AZD0120 - Regimen 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD0120 - Regimen 2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 24,
      "start_date": "2025-12-09",
      "completion_date": "2028-12-07",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-06-07T19:51:25.486Z",
      "location_count": 9,
      "location_summary": "Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 5 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07224373"
    },
    {
      "nct_id": "NCT07139743",
      "title": "Obe-cel in Refractory Progressive Forms of Multiple Sclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Obecabtagene autoleucel (obe-cel)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Autolus Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 18,
      "start_date": "2025-08-04",
      "completion_date": "2029-08-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-06-07T19:51:25.486Z",
      "location_count": 1,
      "location_summary": "Redwood City, California",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07139743"
    },
    {
      "nct_id": "NCT06292923",
      "title": "A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Secondary Progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Foralumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Tiziana Life Sciences LTD",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 54,
      "start_date": "2023-11-15",
      "completion_date": "2025-11",
      "has_results": false,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-06-07T19:51:25.486Z",
      "location_count": 7,
      "location_summary": "North Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "North Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06292923"
    },
    {
      "nct_id": "NCT05359653",
      "title": "Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis (MS)",
        "Multiple Sclerosis, Relapsing-Remitting",
        "Multiple Sclerosis, Primary Progressive",
        "Multiple Sclerosis, Chronic Progressive",
        "Multiple Sclerosis Relapse",
        "Multiple Sclerosis Brain Lesion",
        "Multiple Sclerosis Benign"
      ],
      "interventions": [
        {
          "name": "Clemastine Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 74,
      "start_date": "2023-08-01",
      "completion_date": "2026-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-06-07T19:51:25.486Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05359653"
    },
    {
      "nct_id": "NCT04035005",
      "title": "A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis, Primary Progressive"
      ],
      "interventions": [
        {
          "name": "Ocrelizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1013,
      "start_date": "2019-08-12",
      "completion_date": "2028-01-19",
      "has_results": true,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-06-07T19:51:25.486Z",
      "location_count": 8,
      "location_summary": "Washington D.C., District of Columbia • Clearwater, Florida • Orlando, Florida + 5 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Vero Beach",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04035005"
    },
    {
      "nct_id": "NCT02549703",
      "title": "Mitochondrial Dysfunction and Disease Progression",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Clinically Isolated Syndrome",
        "Relapsing-Remitting Multiple Sclerosis",
        "Secondary Progressive Multiple Sclerosis",
        "Primary Progressive Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2015-09",
      "completion_date": "2018-09-27",
      "has_results": false,
      "last_update_posted_date": "2019-02-20",
      "last_synced_at": "2026-06-07T19:51:25.486Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02549703"
    },
    {
      "nct_id": "NCT07222956",
      "title": "A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis (MS) - Relapsing-remitting",
        "Multiple Sclerosis (MS) Secondary Progressive",
        "Multiple Sclerosis (MS) Primary Progressive"
      ],
      "interventions": [
        {
          "name": "Remibrutinib (Open Label)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Moein Amin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-06-30",
      "completion_date": "2030-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-06-07T19:51:25.486Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07222956"
    },
    {
      "nct_id": "NCT06451159",
      "title": "A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "KYV-101 (Biological) - 0.33 ×10^8 cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "KYV-101 (Biological) - 1 ×10^8 cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy: cyclophosphamide (CYC)",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy: fludarabine (FLU)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bruce Cree",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "25 Years to 70 Years"
      },
      "enrollment_count": 10,
      "start_date": "2024-06-20",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-06-07T19:51:25.486Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06451159"
    },
    {
      "nct_id": "NCT03092544",
      "title": "Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "dimethyl fumarate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Multiple Sclerosis Center of Northeastern New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 57,
      "start_date": "2015-02",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2018-03-22",
      "last_synced_at": "2026-06-07T19:51:25.486Z",
      "location_count": 1,
      "location_summary": "Latham, New York",
      "locations": [
        {
          "city": "Latham",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03092544"
    },
    {
      "nct_id": "NCT02795052",
      "title": "Neurologic Stem Cell Treatment Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neurologic Disorders",
        "Nervous System Diseases",
        "Neurodegenerative Diseases",
        "Neurological Disorders",
        "Stroke",
        "Traumatic Brain Injury",
        "Cadasil",
        "Chronic Traumatic Encephalopathy",
        "Cerebral Infarction",
        "Cerebral Ischemia",
        "Cerebral Stroke",
        "Cerebral Hemorrhage",
        "Parkinson",
        "Multi-System Degeneration",
        "MSA - Multiple System Atrophy",
        "Progressive Supranuclear Palsy",
        "ALS",
        "Amyotrophic Lateral Sclerosis",
        "Neuropathy",
        "Diabetic Neuropathies",
        "Alzheimer Disease",
        "Dementia",
        "Frontotemporal Dementia",
        "Lewy Body Disease",
        "Cognitive Impairment",
        "Lewy Body Variant of Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Intravenous and Intranasal BMSC",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "MD Stem Cells",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2016-06",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-06-06",
      "last_synced_at": "2026-06-07T19:51:25.486Z",
      "location_count": 2,
      "location_summary": "Westport, Connecticut • Coral Springs, Florida",
      "locations": [
        {
          "city": "Westport",
          "state": "Connecticut"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02795052"
    }
  ]
}